Alana Harris Dent

Array ( [id] => 17761529 [patent_doc_number] => 20220235141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => COMBINATION THERAPIES USING CDK INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/613304 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17613304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17761529 [patent_doc_number] => 20220235141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => COMBINATION THERAPIES USING CDK INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/613304 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17613304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17761529 [patent_doc_number] => 20220235141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => COMBINATION THERAPIES USING CDK INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/613304 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17613304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17761529 [patent_doc_number] => 20220235141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => COMBINATION THERAPIES USING CDK INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/613304 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17613304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17593487 [patent_doc_number] => 20220143060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => METHOD FOR TREATING INFECTIOUS DISEASES BY TARGETING NK CELL IMMUNE CHECKPOINT [patent_app_type] => utility [patent_app_number] => 17/441661 [patent_app_country] => US [patent_app_date] => 2020-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7341 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17441661 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17689369 [patent_doc_number] => 20220196662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => AUTOANTIBODIES AS BIOMARKER OF PARANEOPLASTIC ENCEPHALITIS ASSOCIATED WITH TESTICULAR CANCER [patent_app_type] => utility [patent_app_number] => 17/439359 [patent_app_country] => US [patent_app_date] => 2020-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23351 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17439359 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16090417 [patent_doc_number] => 20200199195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/814532 [patent_app_country] => US [patent_app_date] => 2020-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35768 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16814532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17642008 [patent_doc_number] => 20220169746 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => ANTIBODIES TO NEOANTIGENS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/433982 [patent_app_country] => US [patent_app_date] => 2020-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31015 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -92 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17433982 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17383954 [patent_doc_number] => 20220031806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEINS FOR TREATING PD-L1 NEGATIVE TUMORS [patent_app_type] => utility [patent_app_number] => 17/432640 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9834 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17432640 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17503382 [patent_doc_number] => 20220096484 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING CANCER BY TARGETING FATP2 AND MYELOID DERIVED SUPPRESSOR CELLS [patent_app_type] => utility [patent_app_number] => 17/429718 [patent_app_country] => US [patent_app_date] => 2020-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16304 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17577018 [patent_doc_number] => 20220133873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-05 [patent_title] => CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 17/429041 [patent_app_country] => US [patent_app_date] => 2020-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17429041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15931183 [patent_doc_number] => 20200157225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY [patent_app_type] => utility [patent_app_number] => 16/773192 [patent_app_country] => US [patent_app_date] => 2020-01-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16773192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16204915 [patent_doc_number] => 20200237905 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-30 [patent_title] => COMBINATION THERAPY WITH A BET INHIBITOR, A BCL-2 INHIBITOR AND AN ANTI-CD20 ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/752537 [patent_app_country] => US [patent_app_date] => 2020-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12797 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16752537 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17671023 [patent_doc_number] => 20220184190 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-16 [patent_title] => TREATMENT AND DETECTION OF INFECTION AND DISEASE ASSOCIATED WITH DIFFERENT FUNGAL PATHOGENS [patent_app_type] => utility [patent_app_number] => 17/425279 [patent_app_country] => US [patent_app_date] => 2020-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17425279 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16191196 [patent_doc_number] => 20200232045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-23 [patent_title] => METHODS OF IDENTIFYING INDIVIDUALS AT INCREASED RISK OF LUNG CANCER [patent_app_type] => utility [patent_app_number] => 16/751145 [patent_app_country] => US [patent_app_date] => 2020-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12778 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16751145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17520553 [patent_doc_number] => 20220106402 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => ANTIBODY [patent_app_type] => utility [patent_app_number] => 17/423602 [patent_app_country] => US [patent_app_date] => 2020-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14391 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17423602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17521472 [patent_doc_number] => 20220107321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => Cancer Progression Risk Assessment by Microvascular Phenotype [patent_app_type] => utility [patent_app_number] => 17/423583 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17423583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17521472 [patent_doc_number] => 20220107321 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => Cancer Progression Risk Assessment by Microvascular Phenotype [patent_app_type] => utility [patent_app_number] => 17/423583 [patent_app_country] => US [patent_app_date] => 2020-01-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17423583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16114439 [patent_doc_number] => 20200209242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => CANCER DIAGNOSIS USING KI-67 [patent_app_type] => utility [patent_app_number] => 16/736325 [patent_app_country] => US [patent_app_date] => 2020-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10028 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16736325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17473978 [patent_doc_number] => 20220081482 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-17 [patent_title] => ANTICANCER COMPOSITIONS COMPRISING IMMUNE CHECKPOINT INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/419634 [patent_app_country] => US [patent_app_date] => 2019-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11983 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17419634 [rel_patent_id] =>[rel_patent_doc_number] =>)